Changes in Beneficial Ownership · 4
AbCellera Biologics Inc.
ABCLNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1786722614.xml
Filing details
- Report period
- 2026-08-12
- Issuer
- AbCellera Biologics Inc.
- Issuer CIK
- 0001703057
- Trading symbol
- ABCL
Reporting owner 1
- Name
- Hayden Michael R
- Reporting owner CIK
- 0001352908
- Relationship
- Director
- Address
- C/O ABCELLERA BIOLOGICS INC, 150 W 4TH AVENUE, VANCOUVER, BRITISH COLUMBIA, CANADA, A1
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership | Timeliness |
|---|---|---|---|---|---|---|---|---|---|
| Common Shares | 2026-08-12 | P · Form 5 | 46,387 | A | 10.37[F1] | 1,319,784 | I[F2] | See footnote | E |
Table key
- P · Form 5
- Purchase on the market or privately
- A
- Acquired
- I
- Indirect
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Shares | 118,245 | I | By spouse |
Table key
- I
- Indirect
Footnotes
- F1
- The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $10.25 to $10.45. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.↩ 1
- F2
- These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.↩ 1
Signature 1
- Signed
- Tryn Stimart, attorney-in-fact
- Date
- 2026-08-14
Company context
AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more.